Sectors

RVTY
Revvity, Inc.
88.94
200 x 75.43
300 x 93.53
bid
ask
+
1.02
1.16%
250 @ 04:00 PM
88.94 +0.00 (0.00%)
Ytd -8.07%
1y -16.66%
85.80
day range
90.63
82.50
52 week range
117.75
Open 86.28 Prev Close 87.92 Low 85.80 High 90.63 Mkt Cap 9.94B
Vol 786.40K Avg Vol 1.33M EPS 2.06 P/E 43.17 Forward P/E 14.82
Beta 1.11 Short Ratio 7.65 Inst. Own 103.06% Dividend 0.28 Div Yield 0.32
Ex Div Date 04-17 Earning 04-27 50-d Avg 96.44 200-d Avg 95.20 1yr Est 118.93
Earning
Date For Estimate Reported Surprise surprise %
2026-04-27 2026-03 1.02 N/A N/A N/A
2026-02-02 2025-12 1.63 1.7 0.07 4.29%
2025-10-27 2025-09 1.14 1.18 0.04 3.51%
2025-07-28 2025-06 1.14 1.18 0.04 3.51%
2025-04-28 2025-03 0.96 1.01 0.05 5.21%
2025-01-31 2024-12 1.36 1.42 0.06 4.41%
Upgrade / Downgrade
Date Firm Action From To
2026-03-31 JP Morgan Upgrade Neutral Neutral
2026-02-03 JP Morgan Upgrade Neutral Neutral
2026-02-03 TD Cowen Upgrade Buy Buy
2026-02-03 Evercore ISI Group Upgrade Outperform Outperform
2026-02-03 Wells Fargo Upgrade Equal-Weight Equal-Weight
2026-02-03 Barclays Upgrade Overweight Overweight
Profile
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-04-29 BARRETT PETER Director 26.01K Stock Award(Grant)
2025-04-29 CHAPIN SAMUEL R. Director 20.40K Stock Award(Grant)
2026-02-04 GOLDBERG JOEL S General Counsel 106.96K Sale
2026-02-03 KRAKOWIAK MAXWELL Chief Financial Officer 18.77K Stock Award(Grant)
2025-08-26 MICHAS ALEXANDROS P Director 0.00 Sale
2025-08-26 MICHAS ALEXIS P Director 0.00 Sale
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. Rowe Price Investment Management, Inc. 22.45M 2.00B 20.08%
2025-12-30 Vanguard Group Inc 13.16M 1.17B 11.77%
2025-12-30 Price (T.Rowe) Associates Inc 8.61M 765.47M 7.70%
2025-12-30 Edgepoint Investment Group Inc. 8.54M 759.16M 7.63%
2025-12-30 Janus Henderson Group PLC 8.16M 725.85M 7.30%
2025-12-30 Blackrock Inc. 7.18M 638.47M 6.42%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App 14.37M 1.28B 12.85%
2025-12-30 JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund 5.62M 500.25M 5.03%
2025-09-29 -Price (T.Rowe) U.S. Value Equity Trust 3.66M 325.58M 3.27%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 3.57M 317.42M 3.19%
2025-12-30 JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund 3.12M 277.87M 2.79%
2025-12-30 T. Rowe Price Value Fund, Inc. 3.03M 269.27M 2.71%
Dividend
Dividend Date
0.07 2026-04-17
0.07 2026-01-16
0.07 2025-10-17
0.07 2025-07-18
0.07 2025-04-17
0.07 2025-01-17